Collaborations Continue To Be Key For Opdivo’s Development
Executive Summary
Deals with a wide range of companies and academic institutions are exploring nivolumab’s horizons in many solid and hematological malignancies.
You may also be interested in...
Bristol-Myers Taps Academia To Help Research Immuno-Oncology Pipeline
Inspired by the correlative research during the clinical trials for Yervoy, BMS teams up with ten institutions from across the globe to find biomarkers in post-response data.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.